Literature DB >> 12174789

Efficacy of repeated doses of ivermectin against Mansonella perstans.

J Gardon1, J Kamgno, N Gardon-Wendel, B O L Duke, M Boussinesq.   

Abstract

Treatment of Mansonella perstans infection, although seldom necessary, is difficult. In a 3 year's trial of normal and high-dose annual and 3-monthly ivermectin treatment against Onchocerca volvulus, the effects on M. perstans were recorded and related to the cumulative dose received. The World Health Organization's African Programme for Onchocerciasis Control may thus reduce the endemicity of M. perstans.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12174789     DOI： 10.1016/s0035-9203(02)90112-4

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


  3 in total

1.  A randomized trial of doxycycline for Mansonella perstans infection.

Authors:  Yaya I Coulibaly; Benoit Dembele; Abdallah A Diallo; Ettie M Lipner; Salif S Doumbia; Siaka Y Coulibaly; Siaka Konate; Dapa A Diallo; Daniel Yalcouye; Joseph Kubofcik; Ogobara K Doumbo; Abdel K Traore; Adama D Keita; Michael P Fay; Sekou F Traore; Thomas B Nutman; Amy D Klion
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

Review 2.  Broadening the range of use cases for ivermectin - a review of the evidence.

Authors:  Christian Kositz; John Bradley; Harry Hutchins; Anna Last; Umberto D'Alessandro; Michael Marks
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-03-02       Impact factor: 2.455

3.  Validation of onchocerciasis biomarker N-acetyltyramine-O-glucuronide (NATOG).

Authors:  Daniel Globisch; Lisa M Eubanks; Ryan J Shirey; Kenneth M Pfarr; Samuel Wanji; Alexander Y Debrah; Achim Hoerauf; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-05-29       Impact factor: 2.823
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.